BL-8040 1.25 mg/kg + G-CSF + Placebo +G-CSF

Phase 3Active
0 watching 0 views this week๐Ÿ“ˆ Rising
69
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Myeloma

Conditions

Multiple Myeloma

Trial Timeline

Mar 23, 2018 โ†’ Sep 30, 2029

About BL-8040 1.25 mg/kg + G-CSF + Placebo +G-CSF

BL-8040 1.25 mg/kg + G-CSF + Placebo +G-CSF is a phase 3 stage product being developed by BioLineRx for Multiple Myeloma. The current trial status is active. This product is registered under clinical trial identifier NCT03246529. Target conditions include Multiple Myeloma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
2
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT03246529Phase 3Active